(13-172) Medication Use Evaluation of Skyrizi (Risankizumab) – Safety and Efficacy at Harris Health

Wednesday, December 10, 2025

3:15 PM - 4:15 PM

Location: Bayside A, Level 1

Residency Program: Harris Health System
Residency Program Type: PGY2 (Ambulatory Care Pharmacy)
Residency Program Location: Texas

Co-Author(s): Patrice Carmouche-Evans, Wilson Fung, Tasany Lazard

Primary Author(s)